Skip Navigation

Advertise|Press|Contact|FAQ|About Us


Home » Clinical Trials » Alzheimer's Disease

Clinical Trial Details


Research Study Summary

A clinical trial to evaluate treatments using Memantine for patients with Alzheimer's Disease

Research Study Title

The Effect of Memantine on Aggression and Agitation and Its Impact on Caregiver Burden of Patients With Alzheimer's Disease: A 12-week Open-label Study


Alzheimer's disease (AD), is associated with behavioral disturbances in approximately 50% of AD patients in Beijing. Agitation, and aggression specifically, is considered the most serious noncognitive symptom experienced in patients with dementia. Memantine is a recognized treatment for Alzheimer's disease either alone or in combination with cholinesterase inhibitors. Its efficacy in vascular dementia is also established. Family members continue to play a central role in home care for the demented elderly in China. This proposal is to conduct a study in Beijing, China to investigate the efficacy and safety of Memantine in the treatment of agitation and aggression in AD patients. In addition, this proposal aims to explore the impact of memantine on caregiver burden of AD patients in Chinese culture.

To Learn more

Both Male and Female


50 and up

Overall Status


Lead Sponsor

Peking University


69 Months

Facility Type



Both Male and Female ages 50 Years and up

Inclusion Criteria:

  1. Written informed consent

  2. Clinical diagnosis of Alzheimer's disease.

  3. Having at least a minimum aggression score on the Cohen-Mansfield Agitation Inventory (CMAI): a score of ≥ 4 on at least 1 aggressive item, or a score of 3 on at least 2 aggressive items, or a score of 2 on at least 3 aggressive items, or 2 aggressive items occurring at a frequency of 2 and 1 at a frequency of 3.

  4. Availability of a responsible family member or carer to ensure treatment compliance and provide information for informant assessments.

Exclusion Criteria:

  1. Unavailability of a responsible family member or carer

  2. Severe renal impairment.

  3. History of seizures

  4. Diagnosis of any concomitant life threatening illness.

Site Locations (1)

Country State City Zip Facility and Contact
China Beijing 100083 Peking University Institute of Mental Health
Huali Wang, MD, PhD

Huali Wang, MD, PhD
Principal Investigator

Tao Li, MD


Huali Wang, MD, PhD

NCT ID: NCT00703430

Date Last Changed: January 24, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.